48.42 USD
↘ 0.81 (1.65%)AT CLOSE (11:59 AM EDT)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSANASDAQ • USD
47.19
↘ 1.23 (2.54%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
47.19
↘ 1.23 (2.54%)
Market: CLOSED
Open?$48.98
High?$49.99
Low?$48.21
Prev. Close?$49.23
Volume?344.6K
Avg. Volume?706.4K
VWAP?$48.73
Rel. Volume?0.49x
Bid / Ask
Bid?$46.09 × 100
Ask?$48.69 × 2.1K
Spread?$2.60
Midpoint?$47.39
Valuation & Ratios
Market Cap?3.7B
Shares Out?46.3M
Float?38.9M
Float %?84.2%
P/E Ratio?50.99
P/B Ratio?6.15
EPS?$0.95
Dividend?0.00%
Ex-Dividend?N/A
Shares of Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) are trading at $48.42. KNSA shows a split signal: underlying fundamentals suggest "Buy" while technical indicators indicate "Sell". Notable factors include a robust Altman Z-Score and a bullish Golden Cross on the moving averages. Valuation metrics place KNSA at a fair price relative to peers.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Address
105 PICCADILLY, SECOND FLOOR
LONDON, W1J 7NJ
Phone: (781) 431-9100
LONDON, W1J 7NJ
Phone: (781) 431-9100
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?100
Momentum?87
Short Sent.?65
Piotroski F-Score?5/9Mixed
Altman Z-Score?11.36Safe
Confidence?70%Moderate
Short InterestHigh
Short % of Float?8.16%Elevated
Short Interest?3.2M
Days to Cover?5.6
Free Float38.9M
Avg Daily Volume572.5K
Settlement Date2026-05-15
Financial Health
Current Ratio?3.79Strong
Quick Ratio?3.33Strong
Cash Ratio?1.21Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score56/100
P/E?51.0PRICEY▾
Peers100
S&P12
P/B?6.15FAIR▾
Peers100
S&P30
P/S?4.94FAIR▾
Peers100
S&P29
P/FCF?22.7FAIR▾
Peers100
S&P46
EV/EBITDA?38.1HIGH▾
Peers100
S&P7
EV/Sales?4.79FAIR▾
Peers100
S&P38
Returns & Efficiency
ROE?12.1%STRONG▾
Peers50
S&P43
ROA?8.9%STRONG▾
Peers50
S&P70
Cash Flow & Enterprise
FCF?$164.2M
Enterprise Value?$3.6B
Fundamentals ratios updated end of day